Incidence of Hepatic Decompensation After Nucleos(t)ide Analog Withdrawal: Results From a Large, International, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study)
Journal
The American journal of gastroenterology
Journal Volume
118
Journal Issue
9
Pages
1601
Date Issued
2023-09-01
Author(s)
Hirode, Grishma
Hansen, Bettina E
Chen, Chien-Hung
Wong, Grace
Seto, Wai-Kay
Van Hees, Stijn
Papatheodoridi, Margarita
Brakenhoff, Sylvia M
Lens, Sabela
Choi, Hannah S J
Chien, Rong-Nan
Feld, Jordan J
Forns, Xavier
Sonneveld, Milan J
Papatheodoridis, George V
Vanwolleghem, Thomas
Yuen, Man-Fung
Chan, Henry L Y
Kao, Jia-Horng
Hsu, Yao-Chun
Cornberg, Markus
Jeng, Wen-Juei
Janssen, Harry L A
Abstract
Despite improvements in the management of chronic hepatitis B (CHB), risk of cirrhosis and hepatocellular carcinoma remains. While hepatitis B surface antigen loss is the optimal end point, safe discontinuation of nucleos(t)ide analog (NA) therapy is controversial because of the possibility of severe or fatal reactivation flares.
Subjects
decompensation | finite therapy | HBV | hepatic failure
SDGs
Type
journal article